FILANA THERAPEUTICS, INC. (FLNA) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US14817C1071
FILANA THERAPEUTICS, INC. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -95.39 m USD |
| EBIT | -90.97 m USD |
| Net income | -90.97 m USD |
| Diluted EPS – continuing operations | -1.88 USD |
Full history since 2009, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About FILANA THERAPEUTICS, INC.
Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.
More stocks
- AgEagle Aerial Systems Inc. (UAVS)
- Stran & Company, Inc. (SWAG)
- VIVOS INC (RDGL)
- TherapeuticsMD, Inc. (TXMD)
- Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
- STEM, INC. (STEM)
- China Foods Holdings Ltd. (CFOO)
- INTERNATIONAL BATTERY METALS LTD. (IBATF)
- PAID INC (PAYD)
- Bimergen Energy Corp (BESS)
- Binah Capital Group, Inc. (BCG)
- CYBERLOQ TECHNOLOGIES, INC. (CLOQ)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.